Jáuregui AR, Fernández LMD, Skromne KD, Toledo ZC, Ruesga ZE, Estrada GJ, Palomo VA

Language: Spanish
References: 11
Page: 25-29
PDF size: 92.75 Kb.

ABSTRACT

Patients with microvascular angina or Syndrome X have a wide clinical presentation and they are able to remain asymptomatic however with myocardial ischemia even with medical treatment. The objective of this study is to analyze the effect of enalapril over myocardial ischemia stress induced in patients with Syndrome X and medical treatment. We studied 78 and selected 22 patients for our paper. Three of them have stable angina 19 without symptoms but everybody with myocardial ischemia across stress testing and thallium ₂₀₁. Previously they had signed a consent and the Investigational Committee of our Hospital had approved this protocol. After, we did laboratory parameters, stress testing agree Bruce’s protocol and, Color Doppler echocardiography. Then 10 mg of enalapril was administered to patients across 6 weeks and the same parameters were done. Results: Collateral effects were no detected and all patients remained in the protocol. There aren’t changes in laboratory parameters. In stress testing were reviewed heart rate 86 ± 6 versus 88 ± 5%; maximum stress tolerance 418 ± 176 versus 426 ± 165; ST segment depress level 1.8 ± 0.9 mV versus 1.5 ± 1.4 mV and time of ST depress 312 ± 55 versus 348 ± 54 sec. There aren’t significative difference between these measures. Echocardiographic study was useful to review functional changes and left ventricular ejection fraction; with this method three patients with hypokinesis were founded and, after of treatment one of them had not this trouble without significative difference. Conclusions: It’s suggested that enalapril doesn’t produce beneficial effects in these patients, however, it’s a small sample and short time treatment.

REFERENCES

1. Jáuregui R, Skromne D, Toledo C, Ruesga E et al. El espectro clínico del síndrome X. Rev Mex Cardiol 1997; 8: 39-44.

2. Sax FL, Cannon RO, Hanson C, Epstein SE. Impaired forearm vasodilator reserve in patients with microvascular angina: Evidence of a generalized disorder of vascular function? N Engl J Med 1987; 317: 1366-1370.

3. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on induced angina and ST segment depress in patients with microvascular angina. J Am Coll Cardiol 1994; 23: 652-657.

4. Godsland IF. Insulin resistance syndrome in postmenopausal women with cardiological syndrome X. Br Heart J 1995; 74: 47-52.

5. Jáuregui R, Skromne D, Ruesga E. Transformación conceptual en sindrome X. Rev Mex Cardiol 1996; 7: 5-6.

6. Isordia I, Jáuregui R, Chávez A, Toledo C et al. Hiperfibrinogenemia como posible mecanismo hemorreológico de la angina microvascular. Rev Mex Cardiol 1997; 8: 10-14.

7. Gibbs JS, Crean PA, Mockus L, Wright C et al. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 1989; 62: 112-117.

8. Nava G, Monteverde C, Jáuregui R. Síndrome X. Signos angiográficos. Arch Inst Cardiol Méx 1989; 59: 257-265.

9. Jáuregui R, Skromne D, Ruesga E, García A y cols. Síndrome X como etiología del infarto miocárdico. Rev Mex Cardiol 1996; 7: 45-48.

10. Rogacka D, Guzik P, Dziarmaga M, Rzezniczack J et al. The influence of trimetazidine therapy on clinical symptoms and exercise tolerance in patients with syndrome X. A pilot study. J Am Coll Cardiol 1998; 28 (suppl): C705

11. Cannon R0, Brush J, Schenke W, Tracy C, Epstein S. Beneficial and detrimental effects of lidoflazine in microvascular angina. Am J Cardiol 1990; 66: 37-41.